Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 1834942
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BAY 1834942 (tinurilimab) is a humanized immunoglobulin G subclass 2 (IgG2) monoclonal antibody developed by Bayer that targets carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6, also known as CD66c). CEACAM6 is an immune checkpoint regulator that is frequently overexpressed in various solid tumors, where it acts to suppress the activity of effector T cells. By binding to CEACAM6, BAY 1834942 blocks its immunosuppressive interaction with CEACAM1 on activated T cells, thereby restoring the immune system's ability to mount an antitumor response. The drug was evaluated in a Phase I clinical trial for patients with advanced solid tumors, including non-small cell lung adenocarcinoma, colorectal carcinoma, gastric adenocarcinoma, and pancreatic cancer. However, the clinical development of BAY 1834942 was discontinued following the termination of the initial study.
- Other names
- tinurilimab
02
Targets
CEACAM6
Beyond the preview
Go deeper on BAY 1834942.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY 1834942.